Literature DB >> 19557829

Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Geir I Nedredal1, Bruce P Amiot, Peter Nyberg, Jennifer Luebke-Wheeler, Joseph B Lillegard, Travis J McKenzie, Scott L Nyberg.   

Abstract

This study was designed to determine optimal operating conditions of a bioartificial liver (BAL) based on mass transfer of representative hepatotoxins and mediators of immune damage. A microprocessor-controlled BAL was used to study mass transfer between patient and cell compartments separated by a hollow fiber membrane. Membrane permeability (70, 150, or 400 kDa molecular weight cut-off-MWCO), membrane convection (high: 50 mL/min; medium: 25 mL/min; low: 10 mL/min; diffusion: 0 mL/min), and albumin concentration in the cell compartment (0.5 or 5 g%) were considered for a total of 24 test conditions. Initially, the patient compartment contained pig plasma supplemented with ammonia (0.017 kDa), unconjugated bilirubin (0.585 kDa), conjugated bilirubin (0.760 kDa), TNF-alpha (17 kDa), pig albumin (67 kDa), pig IgG (147 kDa), and pig IgM (900 kDa). Mass transfer of each substance was determined by its rate of appearance in the cell compartment. Membrane fouling was assessed by dextran polymer technique. Of the three tested variables (membrane pore size, convection, and albumin concentration), membrane permeability had the greatest impact on mass transfer (P < 0.001). Mass transfer of all toxins was greatest under high convection with a 400 kDa membrane. Transfer of IgG and IgM was insignificant under all conditions. Bilirubin transfer was increased under high albumin conditions (P = 0.055). Fouling of membranes ranged from 7% (400 kDa), 24% (150 kDa) to 62% (70 kDa) during a 2-h test interval. In conclusion, optimal toxin removal was achieved under high convection with a 400-kDa membrane, a condition which should provide adequate immunoprotection of hepatocytes in the BAL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557829      PMCID: PMC2866646          DOI: 10.1002/bit.22450

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  23 in total

1.  Plasma versus whole blood perfusion in a bioartificial liver assist device.

Authors:  John F Patzer; Brian Campbell; Richard Miller
Journal:  ASAIO J       Date:  2002 May-Jun       Impact factor: 2.872

2.  Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver.

Authors:  Scott L Nyberg; Joseph Hardin; Bruce Amiot; Upendra A Argikar; Rory P Remmel; Piero Rinaldo
Journal:  Liver Transpl       Date:  2005-08       Impact factor: 5.799

3.  Hybrid bioartificial liver in hepatic failure: preliminary clinical report.

Authors:  K N Matsumura; G R Guevara; H Huston; W L Hamilton; M Rikimaru; G Yamasaki; M S Matsumura
Journal:  Surgery       Date:  1987-01       Impact factor: 3.982

Review 4.  Technology insight: liver support systems.

Authors:  J Michael Millis; Julian E Losanoff
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-09

Review 5.  A bioartificial liver--state of the art.

Authors:  Alastair J Strain; James M Neuberger
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

6.  Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.

Authors:  Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 7.  Artificial and bioartificial liver support.

Authors:  Travis J McKenzie; Joseph B Lillegard; Scott L Nyberg
Journal:  Semin Liver Dis       Date:  2008-05       Impact factor: 6.115

8.  Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact.

Authors:  J Michael Millis; David C Cronin; Robert Johnson; Hari Conjeevaram; Carol Conlin; Sharon Trevino; Patrick Maguire
Journal:  Transplantation       Date:  2002-12-27       Impact factor: 4.939

9.  Immunoprotection of xenocytes in a hollow fiber bioartificial liver.

Authors:  S L Nyberg; J L Platt; K Shirabe; W D Payne; W S Hu; F B Cerra
Journal:  ASAIO J       Date:  1992 Jul-Sep       Impact factor: 2.872

10.  Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system.

Authors:  L Wang; J Sun; L Li; D Mears; M Horvat; A G Sheil
Journal:  Cell Transplant       Date:  1998 Sep-Oct       Impact factor: 4.139

View more
  3 in total

1.  Pivotal preclinical trial of the spheroid reservoir bioartificial liver.

Authors:  Jaime M Glorioso; Shennen A Mao; Brian Rodysill; Taufic Mounajjed; Walter K Kremers; Faysal Elgilani; Raymond D Hickey; Hakon Haugaa; Christopher F Rose; Bruce Amiot; Scott L Nyberg
Journal:  J Hepatol       Date:  2015-03-25       Impact factor: 25.083

2.  Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure.

Authors:  Harvey S Chen; Dong Jin Joo; Mohammed Shaheen; Yi Li; Yujia Wang; Jian Yang; Clara T Nicolas; Kelly Predmore; Bruce Amiot; Gregory Michalak; Taofic Mounajjed; Jeff Fidler; Walter K Kremers; Scott L Nyberg
Journal:  Hepatology       Date:  2018-12-27       Impact factor: 17.425

3.  A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes.

Authors:  Masaya Iwamuro; Hidenori Shiraha; Shuhei Nakaji; Masumi Furutani; Naoya Kobayashi; Akinobu Takaki; Kazuhide Yamamoto
Journal:  Biomed Eng Online       Date:  2012-12-07       Impact factor: 2.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.